SCHEMBL703058

SCHEMBL703058

CC(=O)OC1C(n2ccc(=O)[nH]c2=O)OC(C(=O)ON2Cc3ccccc3C2=O)(C(O[SiH2]C(C)(C)C)(c2ccccc2)c2ccccc2)C1O[Si](c1ccccc1)(c1ccccc1)C(C)(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL707766 0.80 TDP1 (0.33)
SCHEMBL705473 0.74 TDP1 (0.32)
SCHEMBL711089 0.70 DUT (0.30)
SCHEMBL703057 0.69 TDP1 (0.33)
SCHEMBL707765 0.69 TDP1 (0.35)
SCHEMBL705316 0.69 P2RY6 (0.34)
SCHEMBL705464 0.68
SCHEMBL705472 0.66 TDP1 (0.35)
SCHEMBL703056 0.66 TDP1 (0.32)
SCHEMBL707764 0.66 TDP1 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1670896-B1 CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY ISIS PHARMACEUTICALS INC (US) 2015-01-07 EP disclosed
US-20140357856-A1 CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY ISIS PHARMACEUTICALS, INC. (US) 2014-12-04 US disclosed
US-8791083-B2 Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry ISIS PHARMACEUTICALS, INC. (US) 2014-07-29 US disclosed
EP-1562971-B1 POLYCYCLIC SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION ISIS PHARMACEUTICALS INC (US) 2014-02-12 EP disclosed
US-8124745-B2 Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation ISIS PHARMACEUTICALS, INC (US) 2012-02-28 US disclosed
US-20100216982-A1 POLYCYCLIC SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION Isis Pharmaceutiacls, Inc. (US) 2010-08-26 US disclosed
US-7696345-B2 Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation ISIS PHARMACEUTICALS, INC. (US) 2010-04-13 US disclosed
US-20090258931-A1 CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY ISIS PHARMACEUTICALS, INC. (US) 2009-10-15 US disclosed
EP-1670896-A4 CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY ISIS PHARMACEUTICALS INC (US) 2009-03-04 EP disclosed
EP-1562971-A4 POLYCYCLIC SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION ISIS PHARMACEUTICALS INC (US) 2008-03-05 EP disclosed
US-20080039618-A1 POLYCYCLIC SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION ALLERSON CHARLES 2008-02-14 US disclosed
EP-1670896-A2 CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY ISIS PHARMACEUTICALS, INC. (US) 2006-06-21 EP disclosed
EP-1562971-A2 POLYCYCLIC SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION Isis Pharmaceuticals, Inc. (US) 2005-08-17 EP disclosed
US-20050142581-A1 Microrna as ligands and target molecules ISIS PHARMACEUTICALS, INC. 2005-06-30 US disclosed
US-20050074801-A1 Nucleosides; solid phase synthesis; biochemical conjugation; for lowering cholesterol, triglyceride, plasma leptin, glucose, and/or plasma insulin levels; for lowering body weight ISIS PHARMACEUTICALS, INC. 2005-04-07 US disclosed
WO-2005023995-A2 CHIMERIC OLIGOMERIC COMPOUNDS COMPRISING ALTERNATING REGIONS OF NORTHERN AND SOUTHERN CONFORMATIONAL GEOMETRY ISIS PHARMACEUTICALS, INC. (US) 2005-03-17 WO disclosed
WO-2005023986-A2 MICRORNA AS LIGANDS AND TARGET MOLECULES ISIS PHARMACEUTICALS, INC. (US) 2005-03-17 WO disclosed
US-20040171570-A1 Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation IONIS PHARMACEUTICALS, INC. 2004-09-02 US disclosed
WO-2004041889-A2 POLYCYCLIC SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATION ISIS PHARMACEUTICALS, INC. (US) 2004-05-21 WO disclosed